Internal Medicine: Pulmonary Vascular Diseases

Internal Medicine · Clinical Specialties

How it begins

Análisis exhaustivo de la patología vascular del pulmón: desde la fisiopatología del lecho vascular pulmonar hasta el diagnóstico hemodinámico, las clasificaciones actualizadas (Niza 2022) y los algoritmos terapéuticos de última generación en hipertensión pulmonar, tromboembolia pulmonar y vasculitis.

What it covers

1. Physiology of Pulmonary Circulation
2. · 1.1 Normal Hemodynamic Parameters
3. · 1.2 Regulation of Pulmonary Vasomotor Tone
4. · 1.3 Response of the Right Ventricle to Pressure Overload
5. Classification of Pulmonary Hypertension (Nice 2022)
6. Pathogenesis of Pulmonary Arterial Hypertension (PAH)
7. · 3.1 Genetic and Molecular Base
8. · 3.2 The "Multiple Hit Model"
9. · 3.3 Histological Lesions of Vascular Remodeling
10. Diagnosis of PAH: Algorithm and Key Tests
11. · 4.1 Clinical Presentation
12. · 4.2 Stepwise Diagnostic Algorithm
13. Risk Stratification in PAH
14. · 5.1 Stratification Parameters
15. Treatment of PAH: Stepped Algorithm and Specific Drugs
16. · 6.1 General Measures
17. · 6.2 Specific Therapeutic Targets — The Three Ways
18. · 6.3 Pharmacology of Specific Agents
19. · 6.4 Initial Combination and Therapeutic Escalation Algorithm (ESC/ERS 2022)
20. · 6.5 Lung Transplant in PAH
21. · 6.6 New Therapeutic Targets under Investigation
22. HP Groups 2-5: Differential Characteristics and Management
23. · 7.1 Group 2: PH due to Left Heart Disease
24. · 7.2 Group 3: PH due to Pneumopathy and Chronic Hypoxia
25. · 7.3 Group 5: HP of Multifactorial Mechanisms
26. Pulmonary Thromboembolism (PTE): Diagnosis and Treatment
27. · 8.1 Pathophysiology of Acute PE
28. · 8.2 Risk Classification of Acute PE (ESC 2019)
29. · 8.3 Diagnosis of Acute PE
30. · 8.4 Treatment of PE
31. Chronic Thromboembolic HP (CTEPH) — Group 4
32. · 9.1 Diagnosis of CTEPH
33. · 9.2 Treatment of CTEPH
34. Pulmonary Vasculitis
35. · 10.1 Small Vessel Vasculitis Associated with ANCA
36. · 10.2 Goodpasture Syndrome (Anti-GBM Disease)
37. Pulmonary Arteriovenous Malformations (PAVMs) and Hereditary Hemorrhagic Telangiectasia (HHT)
38. · 11.1 Pathophysiological consequences of PAVMs
39. · 11.2 Diagnosis
40. · 11.3 Treatment of PAVMs
41. Cor Pulmonale
42. Special Syndromes: Portopulmonary Hypertension and Hepatopulmonary Syndrome
43. · 13.1 Portopulmonary Hypertension (PPH)
44. · 13.2 Hepatopulmonary Syndrome (HPS)
45. · 13.3 PVOD and Pulmonary Capillary Hemangiomatosis (PCH)